NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
10.53
-0.15 (-1.40%)
At close: Apr 1, 2026, 4:00 PM EDT
10.60
+0.07 (0.66%)
After-hours: Apr 1, 2026, 5:31 PM EDT
NextCure Employees
NextCure had 40 employees as of December 31, 2025. The number of employees decreased by 3 or -6.98% compared to the previous year.
Employees
40
Change (1Y)
-3
Growth (1Y)
-6.98%
Revenue / Employee
n/a
Profits / Employee
-$1,396,100
Market Cap
37.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 40 | -3 | -6.98% |
| Dec 31, 2024 | 43 | -39 | -47.56% |
| Dec 31, 2023 | 82 | -17 | -17.17% |
| Dec 31, 2022 | 99 | 12 | 13.79% |
| Dec 31, 2021 | 87 | -3 | -3.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 123 |
| Werewolf Therapeutics | 39 |
| Palatin Technologies | 29 |
| Plus Therapeutics | 28 |
| Veru Inc. | 20 |
| Sensei Biotherapeutics | 15 |
| CervoMed | 15 |
NXTC News
- 1 day ago - NextCure and Simcere's SIM0505 (CDH6 ADC) Abstract Accepted for ASCO 2026 - GlobeNewsWire
- 27 days ago - NextCure Provides Business Update and Reports Full Year 2025 Financial Results - GlobeNewsWire
- 2 months ago - NextCure Provides Business Update - GlobeNewsWire
- 4 months ago - NextCure to Present at the Piper Sandler 37th Annual Healthcare Conference - GlobeNewsWire
- 4 months ago - NextCure Announces Closing of $21.5 Million PIPE Financing in Advance of First Half 2026 Phase 1 POC Data Readouts - GlobeNewsWire
- 5 months ago - NextCure Announces $21.5 Million Private Placement of Common Stock Priced at the Market Under Nasdaq Rules - GlobeNewsWire
- 5 months ago - NextCure Provides Business Update and Reports Third Quarter 2025 Financial Results - GlobeNewsWire
- 5 months ago - NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States - GlobeNewsWire